Company News

Sytheon Raises the Limit of Isosorbide Esters to the Max – From Skin Care to Brain Care

Publishes research findings comparing DMF treatment to IDMF treatment.

Dimethyl fumarate (DMF), trade named Tecfidera, with over $4 billion annual sales, is marketed by Biogen as a first-line therapy for the relapse-remitting multiple sclerosis (RRMS) subtype. DMF treatment, however, is limited in some RRMS patients due to adverse effects (e.g., gastrointestinal symptoms, flushing, and lymphopenia). This has increased focus on development of new fumarates that may have similar efficacy to DMF but will be more tolerable for RRMS patients. Sytheon focused on RNA-seq ...

Continue reading this story and get 24/7 access to Happi for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Happi Newsletters